comprehensive -WSS

comprehensive

author：leisure time 2025-08-25 05:57:05 - browse：3823

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： New warning issued for rebooking air travel after delays, cancellations

focus

WSS

New warning issued for rebooking air travel after delays, cancellations

Biden report: The neurospychology of memory and aging

Why the Crimean Bridge is key to Russia's war in Ukraine

For Medicare Advantage, Democrats want stronger protections around AI

Plane’s emergency slide plummets from sky, hits Chicago home

A disappointing year of Humira biosimilars

focus

comprehensive

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Trump got a 'target letter.' What is one and what does it mean?

Heart attack and stroke risk calculators need revising

Gilead might be held responsible for not developing a drug

Peter Hotez and the public health issue of online harassment

Industry veterans launch new biotech VC with $310M

In age of alternative facts, a scholarly course on calling out crap

The kidney, in all its complexity, is captured in a new atlas

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

States increasingly look to regulate hospital facility fees

Wikipedia

The dental labor crisis is a moment of opportunity

The kidney, in all its complexity, is captured in a new atlas

Medical experts are missing from AI regulatory conversations

What we’ve learned from the Aduhelm mess

The Readout: Gilead, Bernie Sanders, and other pharma news

Resistance to cancer drugs: A new genetic explanation

Wikipedia

focus

focus

hotspot